UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 13, 2016
Idera Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
|
001-31918 |
|
04-3072298 |
|
(State or Other Jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer |
|
167 Sidney Street |
|
02139 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (617) 679-5500
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07. Submission of Matters to a Vote of Security Holders.
At the 2016 annual meeting of stockholders of Idera Pharmaceuticals, Inc. (the “Company”) held on June 13, 2016 (the “Annual Meeting”), the Company’s stockholders voted in the following manner with respect to the following proposals:
1. The following nominees were elected to the Board as Class III directors for terms expiring at the 2019 annual meeting of stockholders.
|
|
|
For |
|
Withheld |
|
Broker Non- |
|
|
Dr. Sudhir Agrawal |
|
56,190,953 |
|
1,325,036 |
|
41,046,968 |
|
|
Mr. Youssef El Zein |
|
56,935,771 |
|
580,218 |
|
41,046,968 |
|
|
Dr. Mark Goldberg |
|
53,819,491 |
|
3,696,498 |
|
41,046,968 |
|
The terms of the following directors continued after the Annual Meeting:
|
|
Vincent J. Milano |
|
|
|
James A. Geraghty |
|
|
|
Julien C. Baker |
|
|
|
Maxine Gowen |
|
|
|
Kelvin M. Neu, M.D. |
|
|
|
William S. Reardon |
|
2. A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved.
|
For: |
|
55,585,718 |
|
|
Against: |
|
1,820,147 |
|
|
Abstain: |
|
110,124 |
|
|
Broker Non-Votes: |
|
41,046,968 |
|
3. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2016 was ratified.
|
For: |
|
95,375,056 |
|
|
Against: |
|
2,693,954 |
|
|
Abstain: |
|
493,947 |
|
|
Broker Non-Votes: |
|
0 |
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Idera Pharmaceuticals, Inc. | |
|
|
|
|
|
Date: June 17, 2016 |
By: |
/s/ Mark J. Casey |
|
|
|
Mark J. Casey |
|
|
|
Senior Vice President, General Counsel |
|
|
|
and Secretary |